59,614 Shares in Novo Nordisk A/S $NVO Acquired by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 59,614 shares of the company’s stock, valued at approximately $3,308,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Beacon Financial Group raised its holdings in shares of Novo Nordisk A/S by 4.3% in the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after purchasing an additional 178 shares in the last quarter. Kavar Capital Partners Group LLC increased its holdings in Novo Nordisk A/S by 0.6% in the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock valued at $1,811,000 after buying an additional 200 shares during the last quarter. SeaBridge Investment Advisors LLC increased its holdings in Novo Nordisk A/S by 5.7% in the third quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after buying an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC raised its stake in Novo Nordisk A/S by 1.0% in the third quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock valued at $1,170,000 after buying an additional 200 shares in the last quarter. Finally, Revolve Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Morgan Stanley reissued an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Price Performance

NVO stock opened at $48.46 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $216.38 billion, a P/E ratio of 13.97 and a beta of 0.67. The business has a 50 day simple moving average of $53.82 and a 200-day simple moving average of $53.21. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.